The Trump administration is reportedly preparing a five-year pilot program that would allow Medicare and Medicaid to cover weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. While the proposal hasn’t been officially confirmed on CMS or HHS websites, multiple news outlets, including The Washington Post, Newsweek, and Fierce Healthcare, have cited internal government documents outlining the plan.
But behind the headlines lies a troubling truth: this pilot program could funnel billions of taxpayer dollars into Big Pharma’s pockets, while offering patients a short-term fix with long-term consequences.
Big Pharma’s Jackpot, Taxpayers’ Tab
This pilot program is not about empowering patients. It’s about subsidizing pharmaceutical profits.
- Estimated cost to Medicare: $35 billion from 2026 to 2034
- Annual cost per patient: $5,000–$7,000
- GLP-1 drug market forecast: Over $150 billion within the next decade
These drugs are being framed as a public health solution. But they’re also a financial windfall for drugmakers, compliments of the American taxpayers.
The Medical Reality: Temporary Fix, Long-Term Risk
GLP-1 drugs suppress appetite and slow digestion, leading to weight loss. But the side effects are serious and the results don’t last.
- Common side effects: nausea (50%), diarrhea (35%), vomiting (20%)
- Severe risks: thyroid tumors, pancreatitis, kidney failure, gallbladder problems
- Weight regain: Studies show patients gain back two-thirds of their lost weight within a year of stopping the drug
As Jillian Michaels bluntly puts it:
“You get off the drug in a year and go all the way back. You’ve not learned anything. You’ve not built any physical strength or endurance. You haven’t learned how to eat healthy.”
These drugs don’t teach sustainable habits. They create dependency.
The Narrative Shift: From Empowerment to Helplessness
We’re being told that obesity is purely genetic, that healthy eating and exercise don’t work, and that medication is the only answer. But the data tells a different story.
Before the 1950s, less than 5% of American adults were obese. Today, over 232 million Americans (that’s 45.8% of American adults) are categorized as overweight or obese. That’s not a genetic explosion—it’s a lifestyle shift. Increased calorie consumption, decreased physical activity, and a food system designed for profit, not health.
Jillian Michaels calls out the contradiction:
“Ozempic helps facilitate weight loss by making you eat less. Yup. That’s it… Apparently eating less does help you lose weight after all.”
So why the push for expensive drugs with dangerous side effects? Follow the money.
Public Health Shouldn’t Be a Corporate Subsidy
We believe public health dollars should serve the public—not pad corporate profits. Weight-loss drugs may have a role in clinical care, but they should not be fast-tracked into entitlement programs without:
- Rigorous safety data
- Transparent cost-benefit analysis
- Public debate and oversight
Instead of pushing drugs and surgery for 12-year-olds, let’s return to common sense: good food, movement, sleep, and community. And a lot less screen time for all of us and more time MOVING!
Obesity is complex, but it’s not hopeless. We can powerfully influence our health through:
- Nutrition education
- Consistent exercise
- Mental health support
- Community-based wellness
Let’s stop outsourcing our health to corporations and start investing in ourselves. The solution isn’t in a syringe, it’s in sustainable habits, informed choices, hard work & dedication to our personal health and fitness, and rejecting the false narrative that we’re powerless.
Support the Fight
We’re not funded by corporations or special interests—we’re powered by you. If you appreciate the work we’re doing to expose these policies and fight for your constitutional freedoms, please consider making a donation today.
Your support allows us to create more content like this, mobilize citizen activists, and advocate for legislation that puts We the People back in charge.